The northeastern part of the United States is approaching the annual
respiratory syncytial virus (RSV) season, which is November 2014 through March
2015. RSV is the most common cause of bronchiolitis and pneumonia among
children younger than one year old. During RSV season IBC will approve the
monthly administration of Synagis® (palivizumab) for children in
accordance with the 2014-2015 recommendations from the American Academy of
Pediatrics (AAP).
It is mandatory for all participating providers to obtain
Synagis® (palivizumab) through ACRO Pharmaceutical Services, an
independent company. IBC will coordinate with ACRO Pharmaceutical Services to
facilitate delivery of Synagis® (palivizumab) to your
office.
If you have questions about the Synagis® (palivizumab)
distribution program, please contact Customer Service at 1-800-ASK-BLUE
. The October edition of Partners in Health
UpdateSM will include detailed information about how to order
Synagis® (palivizumab), as well as the complete list of
2014-2015 recommendations for Synagis® (palivizumab) from the
AAP.
Learn more
Review Medical Policy #08.00.22l: Immune Prophylaxis for Respiratory
Syncytial Virus to learn more. Visit our
Medical Policy Portal at, select Accept and Go to
Medical Policy Online, and type the policy name or number in the
Search box.
Note: MedImmune, LLC, the maker of Synagis
®
(palivizumab), has a voluntary program called RSV Connection
TM;
however, IBC does not participate in this program.
This is not a statement of benefits. Benefits may vary
according to state requirements, product line (HMO, PPO, etc.), and/or employer
groups. Member coverage can be verified by calling Customer Service at
1-800-ASK-BLUE.